The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Management of Paget's disease of bone
Abstract
Paget's disease of bone is a common condition with a strong genetic component, characterized by focal increases in bone turnover, affecting one or more bones throughout the skeleton. Paget's disease can be asymptomatic but is frequently associated with bone pain, bone deformity, pathological fracture, secondary osteoarthritis and deafness. Inhibitors of osteoclastic bone resorption, such as bisphosphonates and calcitonin, suppress bone turnover and improve bone pain in Paget's disease. Many patients also require therapy with analgesics and anti-inflammatory agents, since pain in Paget's disease can arise not only from increased bone turnover but also from complications such as osteoarthritis and nerve compression syndromes, which do not respond well to antiresorptive therapy. Comparative studies have shown that second- and third-generation bisphosphonates, such as tiludronate, alendronate and risedronate, are more effective than etidronate at inhibiting bone turnover in Paget's disease but they have not been found to be significantly more effective in controlling bone pain. Importantly, none of the treatments that are currently available for Paget's disease have been shown to prevent complications such as deafness, fracture or bone deformity, or to alter the natural history of the disease. More research is required to define the long-term effects of antiresorptive treatment on clinical outcomes in Paget's disease, so that clinicians and their patients can make better-informed choices about the risks and benefits of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcitonin was the first inhibitor of osteoclasts used for treatment of Paget's disease of bone, a common condition characterized by localized increases in bone turnover (129).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [129]
Citations
Cites
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563 · cited 1×
“If such data were forthcoming they would have major implications for patients with familial PDB, since it is now possible to identify people within families who are genetically predisposed to developing the disease [48–50].”
BackgroundMutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., MacPherson, H., Wallace, R. G. H., van Hul, W., Whyte, M. P., Nakatsuka, K., Hovy, L., et al. (2000) · Nature Genetics · doi:10.1038/71667 · Cited by 481
Incidence and Natural History of Paget's Disease of Bone in England and Wales
Van Staa, T. P., Selby, P., Leufkens, H. G. M., Lyles, K., Sprafka, J. M., & Prof. Cooper, C. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.3.465 · Cited by 369
Dr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease.
Hocking, L. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.22.2735 · Cited by 350 · cited 1×
“If such data were forthcoming they would have major implications for patients with familial PDB, since it is now possible to identify people within families who are genetically predisposed to developing the disease [48–50].”
BackgroundPathophysiology and Treatment of Paget's Disease of Bone
Kanis, J. А. (1991) · Medical Entomology and Zoology · Cited by 308
The Management of Paget's Disease of Bone
Delmas, P. D., & Meunier, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360807 · Cited by 277
Cited by
Kimmel, D. B. (2007) · Journal of Dental Research · doi:10.1177/154405910708601102 · Cited by 251
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs
Rondeau, J., Bitsch, F., Bourgier, E., Geiser, M., Hemmig, R., Kroemer, M., Lehmann, S., Ramage, P., Rieffel, S., Strauss, A., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200500059 · Cited by 226
Calcitonin Plays a Critical Role in Regulating Skeletal Mineral Metabolism during Lactation
Woodrow, J. P., Sharpe, C. J., Fudge, N. J., Hoff, A. O., Gagel, R. F., & Kovacs, C. S. (2006) · Endocrinology · doi:10.1210/en.2005-1616 · Cited by 195
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
“Calcitonin was the first inhibitor of osteoclasts used for treatment of Paget’s disease of bone, a common condition characterized by localized increases in bone turnover (129).”
BackgroundDell'atti, C., Cassar‐Pullicino, V. N., Lalam, R. K., Tins, B. J., & Tyrrell, P. N. M. (2007) · Skeletal Radiology · doi:10.1007/s00256-006-0270-6 · Cited by 102
Metadata
- Authors
- Langston, A. L.
- Affiliations
- University of Aberdeen (GB)
- Corresponding author
- Langston, A. L.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-01
- Volume
- 43
- Issue
- 8
- Pages
- 955-959
- ISSN
- 0263-7103 (ISSN-L)
- 1460-2172
- OpenAlex
- W2108958779
- Cited by
- 124
- References
- 50
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 2 · 2015: 7 · 2014: 6 · 2013: 1 · 2012: 6
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British journal of rheumatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- Paget's disease of bone, bisphosphonates, calcitonin, antiresorptive therapy, bone turnover, bone pain, pathological fracture, secondary osteoarthritis, deafness, tiludronate, alendronate, risedronate, etidronate, analgesics, anti-inflammatory agents, treatment risks and benefits
- MeSH terms
- Bone Resorption, Calcium, Diphosphonates, Humans, Osteitis Deformans, Osteoclasts, Pain, Biomarkers, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Paget's disease of bone. https://app.cochat.ai/papers/10.1093/rheumatology/keh243
- The paper
- Langston, A. L. (2004). Management of Paget's disease of bone. Rheumatology. https://doi.org/10.1093/rheumatology/keh243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.